Home›Nephrology› CKD-MBD care should shift from biochemical targets to phenotype-informed, outcome-oriented management
CKD-MBD care should shift from biochemical targets to phenotype-informed, outcome-oriented managementNew approach to managing bone and vascular health in kidney disease
Frontiers in MedicinePublished October 31, 2026Study authors: Guanting Chen, Tao Li, Kang Yang, Yaoxian Wang, Linqi ZhangDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider phenotype-informed, outcome-oriented care in CKD-MBD; biochemical targets alone are not clinical benefit.
This narrative review examines the management of chronic kidney disease-mineral and bone disorder (CKD-MBD) and argues for a shift away from simple biochemical target control toward a phenotype-informed, evidence-graded, outcome-oriented approach. The authors propose organizing care around a multidimensional bone-vascular axis rather than treating individual laboratory abnormalities in isolation.
The review distinguishes mechanistic plausibility from observational association, surrogate-endpoint trials, and hard-endpoint benefit. It contends that biochemical improvement alone is not clinical benefit and that interventions should be evaluated on their ability to improve hard outcomes.
As a narrative review, it does not report a systematic search strategy, sample size, or quantitative synthesis. No primary data, effect estimates, or adverse event rates are provided. The authors acknowledge that evidence is graded across mechanisms and interventions, but certainty is not quantified.
For practice, the review supports a more nuanced, outcome-focused approach to CKD-MBD, but clinicians should recognize that the recommendations are based on expert synthesis rather than systematic evidence review. The absence of pooled estimates limits the ability to draw firm conclusions about specific interventions.
How this fits prior evidence
This review extends prior coverage of kidney disease mechanisms and management by arguing for a phenotype-informed, outcome-oriented approach to CKD-MBD. It aligns with the prior finding that monocyte and macrophage sensing of calciprotein particles triggers inflammasome activation and interleukin-1β release, supporting a mechanistic link between vascular calcification and inflammation. However, unlike the meta-analysis showing H. pylori eradication linked to lower proteinuria and reduced CKD risk, this review provides no quantitative estimates. It also contrasts with the nsMRA findings by emphasizing that biochemical improvements alone do not constitute clinical benefit.
Living with chronic kidney disease often involves a complex condition where mineral and bone metabolism are disrupted. This can lead to problems with both bone health and the hardening of blood vessels, a process known as vascular calcification. Currently, many treatments focus strictly on hitting specific chemical targets in the blood.
Experts are now calling for a shift in how doctors approach this. They argue that simply hitting a chemical target does not always mean a patient will feel better or see better long-term results. Instead, they suggest a plan that focuses on the actual physical characteristics of the patient's bone and blood vessels.
Because this is a narrative review, it does not provide new trial data or specific numbers. It serves as a guide for doctors to move toward care that prioritizes real clinical outcomes over just checking boxes on a lab report. This approach aims to better manage the link between bone health and heart health for those with kidney disease.
What this means for you:
Doctors want to move from just hitting lab targets to treating the actual health of bones and blood vessels.
Common questions
What is CKD-MBD?
CKD-MBD stands for Chronic Kidney Disease-Mineral and Bone Disorder. It is a condition that affects people with kidney disease, where the body's mineral balance is disrupted, leading to issues with bone health and the calcification of blood vessels.
How is the treatment approach changing?
The review suggests moving away from just hitting biochemical targets in lab tests. Instead, it advocates for care based on the actual health of the bone and vascular axis to provide better clinical benefits for patients with kidney disease.
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication that spans early CKD, dialysis and kidney transplantation. It is better understood not as an isolated disturbance of calcium and phosphate metabolism but as a multidimensional, dynamic syndrome in which mineral-endocrine dysregulation, skeletal remodeling, skeletal fragility and structural consequences, and vascular calcification interact to shape patient outcomes. This narrative review argues that management should move beyond the control of biochemical targets toward phenotype-informed, evidence-graded and outcome-oriented care organized around the bone–vascular axis. We first examine why surrogate-based management has under performed and then propose a working multidimensional framework based on four interrelated domains mineral and endocrine status, bone turnover and mineralization, skeletal fragility and structural consequences, vascular calcification and cardiovascular risk, and clinical modifiers and treatment context. We also grade the evidence behind the principal mechanisms and interventions, from phosphate retention, the FGF23-Klotho axis, vitamin D-PTH dysregulation, Wnt/β-catenin signaling and calciprotein particles to inflammation, gut dysbiosis and uremic toxins, distinguishing mechanistic plausibility from observational association, surrogate-endpoint trials and hard-endpoint benefit. We then match diagnostic tools, including bone turnover markers, DXA, HR-pQCT, 18F-NaF PET/CT, vascular calcification scoring, calcification propensity testing and bone biopsy, to the clinical decisions they are meant to inform, and reframe treatment of hyperphosphatemia, secondary hyperparathyroidism, CKD-associated osteoporosis and vascular calcification by multidimensional framework. The recurring theme is that biochemical improvement is not itself benefit: the field needs stratified, testable strategies anchored in fracture, cardiovascular events, hospitalization, mortality, quality of life and physical function.
